Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.
Mugoni V, Panella R, Cheloni G, Chen M, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee JD, Mendez L, Menon AV, Aster JC, Lane AA, Stone RM, Galinsky I, Zamora JC, Lo-Coco F, Bhasin MK, Avigan D, Longo L, Clohessy JG, Pandolfi PP.
Mugoni V, et al. Among authors: pandolfi pp.
Cell Res. 2019 Jun;29(6):446-459. doi: 10.1038/s41422-019-0162-7. Epub 2019 Apr 25.
Cell Res. 2019.
PMID: 31024166
Free PMC article.